Ken Griffin Nurix Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$12.02 - $21.3 $382,236 - $677,340	31,800 Added 739.53%	36,100 $753,000
Q1 2024 May 15, 2024	SELL	$7.77 - $15.66 $12,432 - $25,056	-1,600 Reduced 27.12%	4,300 $63,000
Q4 2023 Feb 14, 2024	SELL	$4.25 - $10.71 $22,525 - $56,763	-5,300 Reduced 47.32%	5,900 $60,000
Q3 2023 Nov 14, 2023	SELL	$7.86 - $10.08 $8,646 - $11,088	-1,100 Reduced 8.94%	11,200 $88,000
Q2 2023 Aug 14, 2023	BUY	$8.7 - $13.28 $88,740 - $135,456	10,200 Added 485.71%	12,300 $122,000
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $13,696 - $21,216	1,600 Added 320.0%	2,100 $18,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $4,930 - $7,295	500 New	500 $5,000

183

66.4M

40.9K

106K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.21B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.